Diet and Lifestyle for Injection Site Reactions on Wegovy (semaglutide 2.4 mg): What Actually Works

How common are injection site reactions on Wegovy?

The number comes from the label's pooled safety data: three placebo-controlled trials in adults with obesity or overweight, treatment up to 68 weeks, 2,116 people on Wegovy 2.4 mg weekly and 1,261 on placebo. Injection site reactions were reported by 1.4% of the Wegovy group and 1% of the placebo group [1].

That is the rate the label reports for Wegovy 2.4 mg injection. It is low, and 1% of people given placebo injections reported one too.

What the label tells you to control

Injection technique is the part of this question the label covers.

• Sites: abdomen, thigh, or upper arm; semaglutide exposure was similar at these sites, with peak levels 1 to 3 days after an injection [1].
• Schedule: once weekly, on the same day each week, at any time of day, with or without meals [1].
• Switching: the label states that the time of day and the injection site can be changed without a dose adjustment [1].
• Inspection: the label instructs patients to visually inspect the injection before each administration and to use it only if the solution is clear, colorless and contains no particles [1].
• Training: the label says patients and their caregivers should be trained on the specific pen or syringe they will use before starting [1].

Does food, drink or a supplement help?

Nothing in the label connects diet to the injection site. Its one dietary instruction belongs to the indication: Wegovy is used with a reduced-calorie diet and increased physical activity to reduce weight and cardiovascular risk, not to treat skin reactions [1]. We found no study that tested a food, an elimination diet, or a supplement against injection site reactions on Wegovy.

Does hydration matter for the skin?

The label's fluid-related warning is about the kidneys, not the skin. It flags acute kidney injury from volume depletion, recorded at 0.4 versus 0.2 cases per 100 patient-years (7 versus 4 adults), more often in people with existing kidney impairment and during dose escalation, and often after gastrointestinal fluid loss [1]. The label says to monitor kidney function in patients reporting reactions that could lead to volume depletion [1]. That is a warning about dehydration from vomiting or diarrhea, not about redness or swelling at the injection site.

A local reaction or a drug allergy?

The two are handled differently in the label. A prior serious hypersensitivity reaction to semaglutide or to any excipient in the injection or tablets is a contraindication to Wegovy [1]. The hypersensitivity warning notes that anaphylactic reactions and angioedema have been reported after marketing, and says to discontinue Wegovy if a hypersensitivity reaction is suspected [1]. Frequency cannot be estimated from these voluntary reports [1].